Search the Newsreel

Miluna Acquisition Corp (MMTX) shows Q2 profit and advances Kukugan merger

Iluvatar CoreX Signals Return to Profit on Investment Gains

Stabilus SE (WBO:STA2) (Q3 2026) Earnings Call Highlights: Strategic Divestiture and Robotics ...

This article first appeared on GuruFocus. Release Date: August 03, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Stabilus SE (WBO:STA2) successfully completed the sale of Fabrica and TECH products, generating an enterprise …

AKTIE IM FOKUS: Stabilus holen Verluste seit Prognose-Einengung auf - 04.08.26 - News

Stabilus Q3 Earnings Call Highlights

Key Points Interested in Stabilus SE? Here are five stocks we like better. Third-quarter performance: Revenue fell approximately 4%–4.5% year over year to nearly €300 million, but adjusted EBIT margin improved to 10.8% from 10.5%, supported by efficiency measures and stronger industrial operations. Deleveraging …

NAUT|Nautilus Biotechnology Inc|Price:0.977|Chg%:-0.053

Nautilus Biotechnology Inc (NAUT) closed at $0.977, experiencing a 5.15% decline. Analysts rate NAUT as a "Strong Buy" with a target price indicating a 284.62% upside. The company is a development-stage life sciences firm focused on proteomics, aiming to democratize access to the human …

Troilus Mining Corp Revenue Breakdown – TSX:TLG

Nautilus Biotechnology, Inc. Revenue Breakdown – NASDAQ:NAUT

The article provides a basic financial overview page for Nautilus Biotechnology, Inc. (NASDAQ:NAUT) on TradingView. It indicates that the market is closed, with no trades, and points to various financial data sections such as statements, statistics, dividends, earnings, and segments. The content primarily outlines …

Nautilus Biotechnology Inc (NAUT) Q2 2026 Earnings Call Highlights: Strategic Shifts and ...

Nautilus Biotechnology Inc (NAUT) has announced a strategic shift of R&D resources towards its proteoform application, showing strong customer interest and initial revenue from collaborations. While facing a net loss of $14.5 million and needing further fundraising, the company highlights its unique proteoform assay …

Nautilus Biotechnology, Inc. 2026: Revenue $190K, EPS ($0.11) — 10-Q Summary

Nautilus Biotechnology, Inc. (NAUT) reported its 2026 quarterly results, generating $190K in revenue and a net loss of ($14.47M), or ($0.11) diluted EPS, showing modest improvement from the previous year. The company began Early Access service sales, reallocated resources to accelerate proteoform assays development, …

Nautilus Biotechnology Inc (NAUT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Nautilus Biotechnology Inc (NAUT), including its current stock price, market cap, and technical indicator ratings. It details the performance of various indicators like MACD, RSI, and Moving Averages, which generally suggest a "Sell" signal for the stock. …

Earnings call transcript: Nautilus Biotechnology beats Q2 2026 EPS forecast

Nautilus Biotechnology (NAUT) reported a smaller-than-expected Q2 2026 loss, beating EPS forecasts by $0.04 and generating $0.2 million in revenue, primarily from grant funding. The company is strategically shifting R&D focus from its Broadscale program to proteoform development due to strong customer demand and …

Nautilus Biotechnology Reports Second Quarter 2026 Financial Results

Nautilus Biotechnology (NASDAQ: NAUT) reported its second-quarter 2026 financial results, including its first-ever revenues driven by a grant from the Michael J. Fox Foundation and an early access program. The company is reallocating resources to accelerate its proteoform applications due to strong customer enthusiasm, …

Nautilus Biotechnology (NASDAQ: NAUT) posts $29.2M loss but holds $129.2M in cash and investments

Nautilus Biotechnology (NASDAQ: NAUT) shifts roadmap after Q2 2026 results

Price to earnings forward of Nautilus Biotechnology, Inc. – NASDAQ:NAUT

This article provides financial information for Nautilus Biotechnology, Inc. (NASDAQ: NAUT), specifically focusing on its forward price-to-earnings ratio. The content is presented within the context of TradingView's platform, offering financial data and market insights for the company.

Nautilus Biotechnology Inc (NAUT) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Nautilus Biotechnology Inc (NAUT), covering operating, investing, and financing activities. It presents financial data from FY2020Q1 to FY2026Q1, highlighting trends in net income, capital expenditures, and free cash flow. The company's operating …

Nautilus Biotechnology Inc (NAUT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Nautilus Biotechnology Inc (NAUT) focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years. The page also presents current stock performance data, including its market …

MMTX|Miluna Acquisition Ord Shs Class A|Price:10.100|

This article provides an overview of Miluna Acquisition Ord Shs Class A (MMTX), a blank check company focused on mergers and acquisitions, excluding targets based in or primarily operating in the People's Republic of China. It details the company's current stock price, market capitalization, …

NAUT Balance Sheet

This page provides the quarterly and annual balance sheets for Nautilus Biotechnology Inc (NAUT), allowing users to assess its financial health, analyze fundamentals, and calculate key financial ratios. It includes detailed breakdowns of assets, liabilities, and shareholders' equity over several quarters and years. The …

Stabilus engt Prognose ein: Vorsichtigerer Blick auf 2026 - Aktie sackt ab

Stabilus SE: Invitation to a Web Conference on Q3 FY2026 Results on August 3, 2026

KOBLENZ, GERMANY - July 22, 2026 (NEWMEDIAWIRE) - Stabilus SE (WKN: STAB1L, ISIN: DE000STAB1L8) invites investors and analysts to a web conference on August 3, 2026, 10:30 a.m. CEST, on the occasion of the publication of its Q3 FY2026 results. In the web conference, …

Stabilus meldet Q3-EBIT 66,1 Mio. EUR: Gewinn steigt, FCF sinkt – Prog

Nautilus Biotechnology (NAUT) to Post Earnings on Tuesday

Iluka Resources (ASX:ILU) Trades Lower as Mining Stocks Face Broad Selling Pressure?

Is Iluka’s New Eneabba Rare Earths Deals Reshaping The Investment Case For Iluka Resources (ASX:ILU)?

Shanghai Iluvatar CoreX Semiconductor plans $800M share sale in Hong Kong

Iluka Resources (ASX:ILU) Gains as Critical Minerals Stock Finds Support

Iluka Resources (ASX:ILU): The Mineral Sands Stock Back on the Market's Radar

Shanghai Iluvatar CoreX Semiconductor (SEHK:9903) Stock Looks Fully Valued After A 42% Monthly Jump

Shanghai Iluvatar CoreX Semiconductor (SEHK:9903) Stock Looks Stretched After Its 49.4x P B Valuation

Iluka Resources (ASX:ILU) Gains Momentum as Rare Earths Sector Stays in Focus

Iluka Resources (ASX:ILU): Is This ASX Mineral Sands Stock Ready for Comeback?